Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies.

A system for measuring the membrane potential of a neuron is disclosed. The system comprises one or more photoacoustic ion indicators, each comprising a metal chelating agent linked to a chromophore molecule. The metal chelating agent is configured to selectively bind to one of sodium ions, calcium ions, and potassium ions. The system further comprises a photoacoustic probe including a laser configured to emit a light signal to the chromophore and an ultrasound transducer configured to receive a photoacoustic signal in response to the light signal. The system further comprises a processor configured to receive the photoacoustic signal from the ultrasound transducer, determine a quantity of photoacoustic ion indicators exhibiting the shift, and calculate a membrane potential of the neuron based on quantity of photoacoustic ion indicators exhibiting the shift.

A system for measuring the membrane potential of a neuron is disclosed. The system comprises one or more photoacoustic ion indicators, each comprising a metal chelating agent linked to a chromophore molecule. The metal chelating agent is configured to selectively bind to one of sodium ions, calcium ions, and potassium ions. The system further comprises a photoacoustic probe including a laser configured to emit a light signal to the chromophore and an ultrasound transducer configured to receive a photoacoustic signal in response to the light signal. The system further comprises a processor configured to receive the photoacoustic signal from the ultrasound transducer, determine a quantity of photoacoustic ion indicators exhibiting the shift, and calculate a membrane potential of the neuron based on quantity of photoacoustic ion indicators exhibiting the shift.

A device for generating microbubbles may include a syringe having a barrel, a plunger and a syringe tip; a converging nozzle; and an aerator. The converging nozzle may have a coupling end, a converging tip opposite the coupling end, an exterior mating surface adjacent the converging tip, and an interior channel that fluidly couples the syringe tip and converging tip. The interior channel may have a diameter that progressively decreases from the coupling end to the converging tip. The converging nozzle may be coupled to the syringe tip. The aerator may have a retention end, a discharge end, an interior air chamber, an interior circumferential lip, and a discharge channel at the discharge end. The retention end may be coupled to the converging nozzle. The interior circumferential lip may abut the exterior mating surface. One or more air channels may fluidly couple the discharge channel and the interior air chamber.

Biocompatible polymeric nanoparticles may include: a biocompatible polymer and/or functional metal nanostructures. The biocompatible polymer may be a polyhydroxyalkanoate (PHA). The functional metal nanostructures may include at least one noble metal, at least one magnetic metal oxide, or mixtures thereof. The biocompatible polymeric nanoparticles may have an average size less than or equal to 200 nanometers (nm).

Acoustically activatable particles having low vaporization energy and methods for making and using same are disclosed. A particle of material includes a first substance that includes at least one component that is a gas 25° C. and atmospheric pressure. A second substance, different from the first substance, encapsulates the first substance to create a droplet or emulsion that is stable at room temperature and atmospheric pressure. At least some of the first substance exists in a gaseous phase at the time of encapsulation of the first substance within the second substance to form a bubble. After formation of the bubble, the bubble is condensed into a liquid phase, which causes the bubble to transform into the droplet or emulsion having a core consisting of a liquid. The droplet or emulsion is an activatable phase change agent that remains a droplet having a core consisting of a liquid at 25° C. and atmospheric pressure. The first substance has a boiling point below 25° C. at atmospheric pressure.

The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultrasound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

A coupling agent composition is provided and includes a plurality of non-toxic components in an amount equal to or greater than 97 weight percent (wt %). The coupling agent composition includes a carrier of water, at least one water soluble polyol selected from the group consisting of propanediol, pentylene glycol, and butylene glycol, a thickening agent having a naturally derived soluble polymer additive selected from a group consisting of xanthan gum, carrageenan, guar, locust bean, sodium hyaluronate, sodium alginate, acacia, tara gum, tamarind seed, succinoglycan, scleroglucan, and mannan, and a balance of incidental impurities.